Valuation: Fortress Biotech, Inc.

Market Cap 94.38M 80.88M 75.78M 69.22M 131M 9B 132M 894M 348M 4.54B 354M 347M 15.03B P/E 2026 *
1.11x
P/E 2027 * -2.83x
Enterprise Value 94.38M 80.88M 75.78M 69.22M 131M 9B 132M 894M 348M 4.54B 354M 347M 15.03B EV / Sales 2026 *
1.2x
EV / Sales 2027 * 0.83x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.49%
1 week+0.44%
Current month-3.07%
1 month-3.12%
3 months+9.58%
6 months+33.97%
Current year+92.83%
1 week 18.02
Extreme 18.023
18.59
1 month 18
Extreme 18
20
Current year 9.49
Extreme 9.49
21.43
1 year 6.27
Extreme 6.27
21.43
3 years 4.72
Extreme 4.72
21.43
5 years 4.72
Extreme 4.72
26.6
10 years 0
Extreme 0
26.69
Manager TitleAgeSince
Chief Executive Officer 71 19/12/2013
Director of Finance/CFO 51 21/02/2012
Director of Finance/CFO 36 15/08/2022
Director TitleAgeSince
Director/Board Member 74 30/11/2008
Chairman 71 19/12/2013
Director/Board Member 63 31/05/2006
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%+0.44% - - 97.72M
+0.61%+2.88%+45.63%+0.39% 82.73B
+0.11%+4.41%-19.21%-35.13% 57.94B
+14.36%+152.27%+526.55%+41.90% 55.45B
+0.76%+3.53%+0.08%+36.18% 52.57B
+1.86%+3.13%+11.49%+174.36% 48.94B
+1.21%+3.87%+61.90%-16.51% 32.23B
+1.36%+5.06%+53.04%+103.13% 25.94B
+8.29%+10.43%+13.32%+212.23% 22.1B
+3.89%+1.08%+61.82%+112.10% 16.55B
Average +3.20%+22.11%+83.85%+69.85% 43.83B
Weighted average by Cap. +3.31%+27.39%+94.09%+49.30%

Financials

2026 *2027 *
Net sales 78.79M 67.52M 63.27M 57.79M 109M 7.51B 110M 746M 291M 3.79B 296M 289M 12.55B 113M 97.04M 90.93M 83.06M 157M 10.8B 158M 1.07B 418M 5.45B 425M 416M 18.04B
Net income 88.25M 75.62M 70.86M 64.72M 122M 8.41B 123M 836M 325M 4.24B 331M 324M 14.06B -37.81M -32.4M -30.36M -27.73M -52.34M -3.6B -52.86M -358M -139M -1.82B -142M -139M -6.02B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
25/08/26 US$18.30 -0.49% 17,064
24/08/26 US$18.39 +0.49% 13,350
21/08/26 US$18.30 +0.16% 8,497
20/08/26 US$18.27 +0.36% 11,627
19/08/26 US$18.21 -0.08% 12,263
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.830USD
Average target price
11.00USD
Spread / Average Target
+288.69%

Quarterly revenue - Rate of surprise